
In November 2021, the US Food and Drug Administration (FDA) market approved Biomarin’s drug, Voxzogo (vosoritide), for five-year-old children and up who have achondroplasia, also known as dwarfism.
The company has now publicized results from a phase II study that included patients with the disease younger than one year of age, according to a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app